MDAT

From Wikipedia, the free encyclopedia
Jump to: navigation, search
MDAT
6,7-Methylenedioxy-2-aminotetralin2.png
Systematic (IUPAC) name
5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-7-amine
Clinical data
Legal status Uncontrolled
Routes Oral
Identifiers
CAS number 101625-35-8 freebase
33446-21-8 hydrochloride salt
ATC code None
PubChem CID 36483
ChemSpider 33531
Chemical data
Formula C11H13NO2 
Mol. mass 191.223 g/mol

6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.

See also[edit]

References[edit]

  1. ^ a b Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry 33 (2): 703–10. doi:10.1021/jm00164a037. PMID 1967651.